Understanding how RAS mutations lead to cancer development
Genetic dissection of oncogenic RAS-driven tumor initiation in vivo
This study is looking at how certain changes in the RAS gene can start the process of cancer, using special mouse models to see when and how these changes happen in normal cells, which could help us find new ways to prevent and treat cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11082339 on NIH RePORTER |
What this research studies
This research investigates the early events that lead to cancer by focusing on mutations in the RAS gene family, which are commonly found in various cancers. By using advanced mouse models, the study aims to pinpoint when and how these mutations occur in normal cells before they lead to tumor formation. The researchers will analyze specific RAS mutations in a controlled environment to better understand their role in cancer initiation. This approach could provide insights into the fundamental biology of cancer and help identify potential targets for prevention and treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a family history of cancers linked to RAS mutations or those diagnosed with early-stage cancers.
Not a fit: Patients with cancers that do not involve RAS mutations or those with advanced-stage cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating cancers associated with RAS mutations.
How similar studies have performed: Previous research has shown promising results in understanding cancer initiation through genetic studies, making this approach both relevant and potentially impactful.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Counter, Christopher M — Duke University
- Study coordinator: Counter, Christopher M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.